))
Episode 36: "NEN Treatments: Focus on Immunotherapy" with Dr. Jennifer Eads
Manage episode 434590267 series 3426844
Sisällön tarjoaa Learn Advocate Connect Neuroendocrine Tumor Society. Learn Advocate Connect Neuroendocrine Tumor Society tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.
ABOUT THIS EPISODE
What is immunotherapy? How effective are they for neuroendocrine neoplasms (NENs)? Dr. Jennifer Eads from Penn Medicine answers common questions about immunotherapy. She discusses the latest in CAR T therapy, DLL3, and vaccine therapy for NENs.
TOP TEN QUESTIONS ABOUT IMMUNOTHERAPY FOR NENS:
- What is immunotherapy? How does it work?
- How does immunotherapy differ from other treatments?
- When is immunotherapy used? Which neuroendocrine cancers are they used for?
- What are the various immunotherapy drugs used for neuroendocrine cancer and how do they work? What are immune checkpoint inhibitors?
- What is CAR-T therapy?
- What is DLL3?
- What is vaccine therapy?
- What side effects might someone have when taking immunotherapy? How does it make me look (will I lose my hair)? How will it make me feel (will I be able to work)? Does immunotherapy cause someone to be immunocompromised? What monitoring needs to be done while on immunotherapy?
- How do you decide when to use immunotherapy, which to use, and for what patient?
- What do you see as the future of immunotherapy in neuroendocrine cancer treatment?
MEET DR. JENNIFER EADS, MD
Dr. Jennifer Eads is an associate professor of medicine at the University of Pennsylvania, Abramson Cancer Center where she is a gastrointestinal medical oncologist focusing on the treatment of and research in patients with neuroendocrine tumors and gastroesophageal cancers. She is the Physician Lead for GI Clinical Research, overseeing the Penn GI clinical research portfolio. She is the Penn institutional principal investigator for the Eastern Cooperative Oncology Group (ECOG-ACRIN) and serves as the Director of the National Clinical Trials Network (NCTN) for the Abramson Cancer Center. She has served as principal investigator for multiple phase I/II/III clinical trials, including as the national study chair for multiple cooperative group trials. She has served on the National Clinical Cancer Network (NCCN) neuroendocrine tumors guidelines committee, is a former member of the North American Neuroendocrine Tumor Society (NANETS) Board of Directors and is currently on the Board of Scientific Advisors for the Neuroendocrine Tumor Research Foundation (NETRF). In 2022, she was named as the ECOG-ACRIN Young Investigator of the Year.
For more information, visit lacnets.org/lacnets-podcast/36
For more information, visit LACNETS.org.
42 jaksoa
Jaa
